Shoubao C. Ma
Donggang Branch
Lanzhou, China
Lanzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Optimizing In Vivo CAR T-cell Engineering for Cancer Immunotherapy.
Journal: Cancer research
Published: August 27, 2025
Emerging role of RNA modification reader YTHDF2 in hematopoiesis, immunity, and cancer.
Journal: MedScience
Published: August 23, 2025
YTHDF2: a key RNA reader and antitumor target.
Journal: Trends in immunology
Published: February 13, 2025
Loss of YTHDF2 enhances Th9 programming and CAR-Th9 cell antitumor efficacy.
Journal: Nature immunology
Published: December 14, 2024
Natural killer cell-based immunotherapy for cancer.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: December 12, 2024
Reduction of myeloid-derived suppressor cells in prostate cancer murine models and patients following white button mushroom treatment.
Journal: Clinical and translational medicine
Published: June 17, 2024
The tumor-intrinsic role of the m6A reader YTHDF2 in regulating immune evasion.
Journal: Science immunology
Published: May 31, 2024
YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis.
Journal: Leukemia
Published: February 01, 2024
The RNA-stability-independent role of the RNA m6A reader YTHDF2 in promoting protein translation to confer tumor chemotherapy resistance.
Journal: Molecular cell
Published: December 23, 2023
Recent Advances of RNA m6A Modifications in Cancer Immunoediting and Immunotherapy.
Journal: Cancer treatment and research
Published: December 19, 2023
Recent advances and remaining challenges in lung cancer therapy.
Journal: Chinese medical journal
Published: October 09, 2023
Last Updated: 09/26/2026